{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-008435","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.889581+00:00","generated_at":"2026-05-15T22:50:53.781036+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kairos Pharma acquires exclusive worldwide rights to CL-273 from Celyn Therapeutics","bullets":["Acquired 100% worldwide rights to CL-273, a pan-EGFR inhibitor for EGFR-mutant NSCLC, from Celyn Therapeutics (backed by OrbiMed and Torrey Pines).","Consideration includes 16.5% of Kairos shares on fully diluted basis, $15M milestone upon FDA submission, and 2% royalty on U.S. net revenues.","CL-273 targets $16.2 billion lung cancer market; addresses resistance to existing EGFR TKIs.","Binding term sheet signed March 2, 2026; closing subject to shareholder and NYSE American approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-008435","json":"https://secwatch.observer/filing/0001493152-26-008435.json","markdown":"https://secwatch.observer/filing/0001493152-26-008435.md","text":"https://secwatch.observer/filing/0001493152-26-008435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226008435/0001493152-26-008435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226008435/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T22:50:53.781036+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a09caefbc0590f540fc5811877e13dc148ba69c","claim":"Kairos Pharma, LTD. entered into Binding Term Sheet with Celyn Therapeutics, Inc. valued at Asset acquisition of CL-273; consideration includes 16.5% fully diluted shares, $15 million mileston (effective 2026-03-02).","evidence_excerpt":"On March 2, 2026, Kairos Pharma, Ltd., a Delaware corporation (the “Company”) entered into a binding term sheet with Celyn Therapeutics, Inc., a privately held biotechnology company (“Celyn”), regarding a proposed asset acquisition of CL-273 (the “Asset Acquisition”), an investigational, reversible, wild type sparing pan EGFR small molecule inhibitor being developed by Eilean Therapeutics for EGFR mutant non small cell lung cancer (the “Term Sheet”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1962011/000149315226008435/0001493152-26-008435-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Celyn Therapeutics, Inc."},{"label":"Value","value":"Asset acquisition of CL-273; consideration includes 16.5% fully diluted shares, $15 million mileston"},{"label":"Effective","value":"2026-03-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}